Participated · Equity · Mar 2026

Congruence Therapeutics is a clinical-stage biotechnology company that uses a computationally driven discovery engine, Revenir, to identify allosteric and cryptic pockets and generate novel small-molecule correctors. Its lead program, CGX-926, is advancing toward a Phase 1/1b study for MC4R-deficient genetic obesity, and the recent $39.5M financing is earmarked to support that trial. The company has built a pipeline of wholly owned programs spanning genetic obesity, GBA Parkinson’s Disease, and α1‑Antitrypsin Deficiency. Congruence also leverages its platform to support research collaborations with large pharmaceutical companies across oncology, metabolic disease, neurology, and immunology. The company is led by CEO Dr. Clarissa Desjardins and is based in Montreal.

Led · Series B · Jan 2026

Mediar Therapeutics focuses on neutralizing fibrosis-driving pathways with human IgG1 antibodies that inhibit specific extracellular proteins. Its lead candidate, MTX-474, an EphrinB2 antagonist, is now in a 90-patient global Phase 2a trial (EncompaSSc) for systemic sclerosis. MTX-463, a WISP1-targeting antibody partnered with Eli Lilly, is enrolling patients in a Phase 2a study for idiopathic pulmonary fibrosis after completing Phase 1. A third program, MTX-439, a SMOC2 antagonist for chronic kidney disease-associated fibrosis, is moving toward Phase 1 in the first half of 2026. Management reports that, including the latest financing and the Lilly partnership, the company has secured approximately $175 million to date, providing runway to advance all three assets through early and mid-stage clinical trials. Mediar’s strategy combines novel targets, blood-based biomarkers, and well-characterized antibody modalities to enable a potential precision-medicine approach in fibrotic diseases.

Led · Seed · Feb 2025

Reverb Therapeutics uses its Amplify•R™ platform, which combines bispecific antibody engineering with data-driven modeling, to modulate endogenous cytokines and redirect them to specific tissues. The platform is designed to avoid systemic toxicity, immunogenicity, and manufacturing issues that have limited prior cytokine therapies. Reverb’s initial focus areas are cancer and autoimmune diseases, and in vivo preclinical studies have shown proof-of-concept for tumor shrinkage and cytokine redirection. Its lead program, AMP01, blocks PD-1 while delivering endogenous IL-15 to expand and activate cytotoxic T cells. With the recently closed financing, the company plans to advance the IL-15 bispecific to candidate stage and to develop additional bispecific programs across other cytokines and cellular targets. Elements of the Amplify•R™ antibodies are reusable, enabling rapid scaling of the pipeline across multiple disease areas.

Led · Series A · Dec 2024

Fluid Biomed is a clinical-stage medical device company based in Calgary, Alberta, developing ReSolv™, the world’s first bioabsorbable polymer-based neurovascular stent for brain aneurysms. The ReSolv™ stent has been validated by years of scientific research and demonstrated functional benefits in a first-in-human clinical study. The technology was developed by co-founders John Wong, M.D. (CEO), and Alim Mitha, M.D. (President and CTO), both academic neurosurgeons at the University of Calgary. The company plans to use recent financing to further validate the ReSolv™ stent and its proprietary delivery system in expanded patient studies and to enable larger clinical trials. Fluid Biomed also intends to broaden its product pipeline with the additional strategic and financial capital. Fluid Biotech is commercializing a hybrid polymer-metal flow-diverting brain stent constructed of bioabsorbable polymer and metal to provide a scaffold that enables better healing and vessel visualization. Led by Dr. John Wong (CEO) and Dr. Alim Mitha (President and CTO), the company aims to cure intracranial aneurysms with this novel device. Fluid closed a $4.7M seed funding round to advance development. The company intends to use the funds to engage contract manufacturers to initiate production, complete regulatory milestones, and plan for first-in-human implantation. In conjunction with the raise, Fluid added two board members with capital and industry experience to support commercialization and regulatory progress. The company is based in Calgary, Alberta, Canada.

Participated · Series C · Oct 2024

Evommune is a Palo Alto-based clinical-stage biotechnology company focused on discovering and developing treatments for immune-mediated inflammatory diseases. Led by CEO Luis Pena, its lead programs include EVO756, a potent, highly selective small-molecule antagonist of MRGPRX2, and EVO301, a long-acting serum albumin-binding injectable therapeutic fusion-protein targeting IL-18 signaling. EVO756 is implicated in mast cell activation and neuroinflammation and is being developed as a potentially targeted, safe oral therapy for multiple mast cell–mediated diseases. EVO301 is designed to neutralize IL-18 signaling to regulate inflammation across chronic inflammatory diseases. The company plans multiple Phase 2 studies of EVO756 and a Phase 2 proof-of-concept study of EVO301. Evommune raised $115M in a Series C and intends to use the proceeds to advance these lead clinical programs. Evommune is a private, clinical-stage R&D biotechnology company focused on treating inflammatory diseases. The company uses a human tissue–based approach to discover, develop, and deliver therapies intended to address symptoms and halt progressive disease. Led by President and CEO Luis Peña, Evommune pursues translational immunology research to advance its therapeutic candidates. Founded in 2020, the company is advancing its pipeline through clinical-stage development. Evommune recently expanded funding for its Series B round, strengthening its financial position for near-term work. The company intends to use the new funds to expand operations and broaden its business reach. Evommune is a clinical-stage biotechnology company discovering and developing therapies to treat inflammatory diseases using a dynamic human tissue-based approach. Its prioritized pipeline includes EVO101, a novel small-molecule IRAK4 inhibitor currently in a Phase 2a proof-of-concept trial for atopic dermatitis, with data expected later this year. The company is also developing EVO756, a preclinical program that targets mast cells by selectively modulating MRGPRX2 to treat chronic spontaneous urticaria and interstitial cystitis. In addition, Evommune runs a discovery program targeting autoimmune diseases via PKCθ. The company intends to use the proceeds from its recent financing to support these three prioritized programs. Evommune was founded in 2020 and is led by President and CEO Luis Peña in Palo Alto, CA. Evommune is a private R&D company and innovation engine that uses the skin as a lens to uncover approaches for accelerating development of medicines across immunology and dermatology. The company has four investigational compounds in its pipeline, three of which were in‑licensed via an exclusive agreement with Dermira, a wholly owned subsidiary of Eli Lilly and Company. Evommune is led by co‑founders Luis Pena (President & CEO), Eugene A. Bauer, M.D. (Chief Medical Officer), and Hans Hofland, PhD (SVP of Research). The company says it is developing transformative therapies to treat patients with immune‑mediated and chronic inflammatory diseases. Evommune recently won the Gore Range Capital Skin Health Innovation Competition at the Fall Clinical Dermatology Conference, reflecting engagement with clinicians and industry thought leaders. The company plans to use its recent funding to continue research and development of its pipeline. Evommune applies a tissue‑based, skin‑centered approach and a novel screening platform to discover molecules aimed at treating chronic inflammatory and dermatologic diseases. The company is building a pipeline intended to include both discovery-stage and clinical‑stage development programs and has established academic and industry collaborations to support that work. Leadership includes industry veterans Luis Peña (CEO), Eugene A. Bauer, MD (CMO), Hans Hofland, PhD (SVP, research), and Janice Drew, MPH (SVP, product development), who previously held senior roles at Dermira. The team highlights a track record of rapid regulatory approvals and drug development across immunology and dermatology; Dermira was sold to Eli Lilly for approximately $1.1 billion in 2020. Evommune says the seed financing will be used to set up and drive execution of its longer‑term strategy to accelerate development of transformative medicines. The company was founded in 2020 and is headquartered in Los Altos, California.